Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis

Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis

Abstract Proteoglycans are promising therapeutic targets in Multiple Sclerosis (MS), because they regulate many aspects of the immune response. This was studied using surfen, an agent that binds both heparan sulphate proteoglycans (HSPGs) and chondroitin sulphate proteoglycans (CSPGs). Initial cell...

Full description

Bibliographic Details
Main Authors: Jordan R. Warford, Anna-Claire Lamport, Derek R. Clements, Alicia Malone, Barry E. Kennedy, Youra Kim, Shashi A. Gujar, David W. Hoskin, Alexander S. Easton
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Acta Neuropathologica Communications
Subjects:
Surfen
Lysolecithin
Proteoglycan
Experimental autoimmune encephalomyelitis
Multiple sclerosis
Online Access:http://link.springer.com/article/10.1186/s40478-017-0506-9

Internet

http://link.springer.com/article/10.1186/s40478-017-0506-9

Similar Items